NEUMORA THERAPEUTICS, INC. (NMRA) EBITDA
- 2026-06-30: Basis Reported; EBITDA -$42.18M*; Operating income -$42.19M; Depreciation and amortization $7.00K*.
- 2026-03-31: Basis Reported; EBITDA -$52.86M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA -$58.47M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA -$57.68M*; Operating income -$57.70M; Depreciation and amortization $23.00K*.
Complete source-backed ebitda history.
- Available history
- 2022-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | -$42.18M* | -$42.19M | $7.00K* | (m) | (m) | (m) | -$39.53M* | (m) | $29.28M | (m) | $0.00 |
|---|
| 2026-03-31 | Reported | -$52.86M | (m) | (m) | (m) | (m) | (m) | -$46.40M | (m) | $38.60M | (m) | $30.00K |
|---|
| 2025-12-31 | Reported | -$58.47M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | -$57.68M* | -$57.70M | $23.00K* | (m) | (m) | (m) | -$46.63M* | (m) | $40.52M | (m) | $0.00 |
|---|
| 2025-06-30 | Reported | -$54.02M* | -$54.04M | $19.00K* | (m) | (m) | (m) | -$52.40M* | (m) | $38.72M | (m) | $25.00K |
|---|
| 2025-03-31 | Reported | -$70.78M | (m) | (m) | (m) | (m) | (m) | -$59.45M | (m) | $52.15M | (m) | $105.00K |
|---|
| 2024-12-31 | Reported | -$62.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2024-09-30 | Reported | -$76.49M* | -$76.65M | $156.00K* | (m) | (m) | (m) | -$33.48M* | (m) | $60.63M | (m) | $53.00K |
|---|
| 2024-06-30 | Reported | -$63.66M* | -$63.82M | $160.00K* | (m) | (m) | (m) | -$56.16M* | (m) | $48.63M | (m) | $125.00K |
|---|
| 2024-03-31 | Reported | -$59.92M | (m) | (m) | (m) | (m) | (m) | -$42.95M | (m) | $45.76M | (m) | (m) |
|---|
| 2023-12-31 | Reported | -$113.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2023-09-30 | Reported | -$56.69M* | -$56.86M | $173.00K* | (m) | (m) | $37.00K* | -$47.77M* | (m) | $41.60M | (m) | (m) |
|---|
| 2023-06-30 | Reported | -$41.89M* | -$42.06M | $171.00K* | (m) | (m) | $0.00* | -$31.02M* | (m) | $32.77M | (m) | (m) |
|---|
| 2023-03-31 | Reported | -$39.01M | (m) | (m) | (m) | (m) | $36.00K | -$33.04M | (m) | $29.48M | (m) | (m) |
|---|
| 2022-12-31 | Reported | -$30.57M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2022-09-30 | Reported | (m) | -$30.60M | (m) | (m) | (m) | (m) | (m) | (m) | $22.55M | (m) | (m) |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | -$240.95M | (m) | (m) | (m) | (m) | (m) | -$206.44M | (m) | $176.06M | (m) | $130.00K |
|---|
| 2024-12-31 | Reported | -$262.83M | (m) | (m) | (m) | (m) | (m) | -$182.94M | (m) | $200.93M | (m) | $178.00K |
|---|
| 2023-12-31 | Reported | -$251.43M | (m) | (m) | (m) | (m) | $117.00K | -$163.28M | (m) | $142.72M | (m) | $268.00K |
|---|
| 2022-12-31 | Reported | -$135.28M | (m) | (m) | (m) | (m) | $511.00K | -$114.90M | (m) | $91.75M | (m) | (m) |
|---|